Risk factors for severe respiratory syncytial virus disease in children with cancer: The importance of lymphopenia and young age

Pediatrics

Volumn 121, Issue 2, 2008, Pages 235-243

  El Saleeby, Chadi M ^a,b,c,d,e   Somes, Grant W ^b   DeVincenzo, John P ^b,c,d   Gaur, Aditya H ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^d LE BONHEUR CHILDREN S HOSPITAL   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Cancer; Lymphopenia; Respiratory syncytial virus; Risk factors

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ARTICLE; CHILD; CHILDHOOD CANCER; CONTROLLED STUDY; DEATH; DISEASE SEVERITY; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNE DEFICIENCY; LABORATORY TEST; LOWER RESPIRATORY TRACT INFECTION; LYMPHOCYTE COUNT; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; NEUTROPENIA; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RISK FACTOR; SEVERE COMBINED IMMUNODEFICIENCY; SOLID TUMOR; VIRUS INFECTION;

AGE FACTORS; CHILD; HUMANS; IMMUNOCOMPROMISED HOST; LEUKEMIA, MYELOID, ACUTE; LYMPHOPENIA; NEOPLASMS; OPPORTUNISTIC INFECTIONS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUSES; RETROSPECTIVE STUDIES; RISK FACTORS; SEVERE COMBINED IMMUNODEFICIENCY;

EID: 38849150519     PISSN: 00314005     EISSN: 02105721     Source Type: Journal    
DOI: 10.1542/peds.2007-1102     Document Type: Article

References (35)

1. Hall CB, Powell KR, MacDonald NE, et al. Respiratory syncytial viral infection in children with compromised immune function. N Engl J Med. 1986;315(2):77-81
2. Couch RB, Englund JA, Whimbey E. Respiratory viral infections in immunocompetent and immunocompromised persons. Am J Med. 1997;102(3A):2-9
3. Small TN, Casson A, Malak SF, et al. Respiratory syncytial virus infection following hematopoietic stem cell transplantation. Bone Marrow Transplant. 2002;29(4):321-327
4. Ebbert JO, Limper AH. Respiratory syncytial virus pneumonitis in immunocompromised adults: clinical features and outcome. Respiration. 2005;72(3):263-269
5. Harrington RD, Hooton TM, Hackman RC, et al. An outbreak of respiratory syncytial virus in a bone marrow transplant center. J Infect Dis. 1992;165(6):987-993
6. Bowden RA. Respiratory virus infections after marrow transplant: the Fred Hutchinson Cancer Research Center experience. Am J Med. 1997;102(3A):27-30
7. Whimbey E, Englund JA, Couch RB. Community respiratory virus infections in immunocompromised patients with cancer. Am J Med. 1997;102(3A):10-18
8. Ghosh S, Champlin RE, Englund J, et al. Respiratory syncytial virus upper respiratory tract illnesses in adult blood and marrow transplant recipients: combination therapy with aerosolized ribavirin and intravenous immunoglobulin. Bone Marrow Transplant. 2000;25(7):751-755
9. Boeckh M, Englund J, Li Y, et al. Randomized controlled multicenter trial of aerosolized ribavirin for respiratory syncytial virus upper respiratory tract infection in hematopoietic cell transplant recipients. Clin Infect Dis. 2007;44(2):245-249
10. Roberts MM, To LB, Gillis D, et al. Immune reconstitution following peripheral blood stem cell transplantation, autologous bone marrow transplantation and allogeneic bone marrow transplantation. Bone Marrow Transplant. 1993;12(5):469-475
11. Mackall CL, Fleisher TA, Brown MR, et al. Lymphocyte depletion during treatment with intensive chemotherapy for cancer. Blood. 1994;84(7):2221-2228
12. Mackall CL. T-cell immunodeficiency following cytotoxic antineoplastic therapy: a review. Oncologist. 1999;4(5):370-378
13. Whimbey E, Champlin RE, Englund JA, et al. Combination therapy with aerosolized ribavirin and intravenous immunoglobulin for respiratory syncytial virus disease in adult bone marrow transplant recipients. Bone Marrow Transplant. 1995;16(3):393-399
14. Ghosh S, Champlin RE, Ueno NT, et al. Respiratory syncytial virus infections in autologous blood and marrow transplant recipients with breast cancer: combination therapy with aerosolized ribavirin and parenteral immunoglobulins. Bone Marrow Transplant. 2001;28(3):271-275
15. Nichols WG, Gooley T, Boeckh M. Community-acquired respiratory syncytial virus and parainfluenza virus infections after hematopoietic stem cell transplantation: the Fred Hutchinson Cancer Research Center experience. Biol Blood Marrow Transplant. 2001;7(suppl):11S-15S
16. Whimbey E, Champlin RE, Couch RB, et al. Community respiratory virus infections among hospitalized adult bone marrow transplant recipients. Clin Infect Dis. 1996;22(5):778-782
17. Machado CM, Boas LS, Mendes AV, et al. Low mortality rates related to respiratory virus infections after bone marrow transplantation. Bone Marrow Transplant. 2003;31(8):695-700
18. Whimbey E, Couch RB, Englund JA, et al. Respiratory syncytial virus pneumonia in hospitalized adult patients with leukemia. Clin Infect Dis. 1995;21(2):376-379
19. Wang EE, Law BJ, Stephens D. Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC) prospective study of risk factors and outcomes in patients hospitalized with respiratory syncytial viral lower respiratory tract infection. J Pediatr. 1995;126(2):212-219
20. Meissner HC. Selected populations at increased risk from respiratory syncytial virus infection. Pediatr Infect Dis J. 2003;22(2 suppl):S40-S44
21. DeVincenzo JP, El Saleeby CM, Bush AJ. Respiratory syncytial virus load predicts disease severity in previously healthy infants. J Infect Dis. 2005;191(11):1861-1868
22. Boeckh MJ, Gooley T, Englund J, et al. Respiratory syncytial virus (RSV) infection in hematopoietic stem cell transplant (HCT) recipients: risk factors for acquisition and lower respiratory tract disease, and impact on mortality. Blood. 2004;104(11):57a (abstract 187) [oral presentation]
23. Ljungman P, Ward KN, Crooks BN, et al. Respiratory virus infections after stem cell transplantation: a prospective study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant. 2001;28(5):479-484
24. Anaissie EJ, Mahfouz TH, Aslan T, et al. The natural history of respiratory syncytial virus infection in cancer and transplant patients: implications for management. Blood. 2004;103(5):1611-1617
25. Abdallah A, Rowland KE, Schepetiuk SK, To LB, Bardy P. An outbreak of respiratory syncytial virus infection in a bone marrow transplant unit: effect on engraftment and outcome of pneumonia without specific antiviral treatment. Bone Marrow Transplant. 2003;32(2):195-203
26. Aslan T, Fassas AB, Desikan R, et al. Patients with multiple myeloma may safely undergo autologous transplantation despite ongoing RSV infection and no ribavirin therapy. Bone Marrow Transplant. 1999;24(5):505-509
27. Cole PD, Suh JS, Onel K, Stiles J, Armstrong D, Dunkel IJ. Benign outcome of RSV infection in children with cancer. Med Pediatr Oncol. 2001;37(1):24-29
28. Crooks BN, Taylor CE, Turner AJ, et al. Respiratory viral infections in primary immune deficiencies: significance and relevance to clinical outcome in a single BMT unit. Bone Marrow Transplant. 2000;26(10):1097-1102
29. DeVincenzo JP, Hirsch RL, Fuentes RJ, Top FH Jr. Respiratory syncytial virus immune globulin treatment of lower respiratory tract infection in pediatric patients undergoing bone marrow transplantation: a compassionate use experience. Bone Marrow Transplant. 2000;25(2):161-165
30. Ljungman P. Respiratory virus infections in stem cell transplant patients: the European experience. Biol Blood Marrow Transplant. 2001;7(suppl):5S-7S
31. Lujan-Zilbermann J, Benaim E, Tong X, Srivastava DK, Patrick CC, DeVincenzo JP. Respiratory virus infections in pediatric hematopoietic stem cell transplantation. Clin Infect Dis. 2001; 33(7):962-968
32. Glezen WP, Taber LH, Frank AL, Kasel JA. Risk of primary infection and reinfection with respiratory syncytial virus. Am J Dis Child. 1986;140(6):543-546
33. El Saleeby CM, Suzich J, Conley ME, DeVincenzo JP. Quantitative effects of palivizumab and donor-derived T cells on chronic respiratory syncytial virus infection, lung disease, and fusion glycoprotein amino acid sequences in a patient before and after bone marrow transplantation. Clin Infect Dis. 2004;39(2):e17-e20
34. Welliver TP, Garofalo RP, Hosakote Y, et al. Severe human lower respiratory tract illness caused by respiratory syncytial virus and influenza virus is characterized by the absence of pulmonary cytotoxic lymphocyte responses. J Infect Dis. 2007;195(8):1126-1136
35. DeVincenzo JP. Respiratory syncytial virus infections in hematopoietic stem cell transplant recipients and other severely immunocompromised patients. Pediatr Pathol Mol Med. 2000;19(2-3):115-132